Actively Recruiting
Atomoxetine and DAW2022 on OSA Severity
Led by Brigham and Women's Hospital · Updated on 2026-03-03
18
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.
CONDITIONS
Official Title
Atomoxetine and DAW2022 on OSA Severity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Moderate-to-severe obstructive sleep apnea with apnea-hypopnea index of 15 or more events per hour
- Age between 21 and 70 years
You will not qualify if you...
- Presence of major organ system disease that prevents physiological measurements
- Use of medications that stimulate or depress respiration, including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, or 4-hydroxybutanoic acid
- Use of SNRIs or SSRIs
- Neuromuscular disease or major neurological disorders
- Heart failure or unstable major medical conditions
- Sleep breathing disorders other than obstructive sleep apnea
- Other sleep disorders such as periodic limb movements with arousal index over 10 per hour, narcolepsy, or parasomnias
- Hypersensitivity to study drugs such as angioedema or urticaria
- Contraindications to DAW2020
- Use of medications that lengthen the QTc interval
- Hypokalemia, hypomagnesemia, or uncontrolled thyroid disease
- Severe claustrophobia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02135
Actively Recruiting
Research Team
L
Ludovico Messineo, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here